Prediction of LVAR and MACE in AMI Though Plasma Multiomics Analysis

NCT ID: NCT06885619

Last Updated: 2025-07-31

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-01-01
• Study Completion Date: 2027-12-31

Brief Summary

To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.

Detailed Description

Despite advances in AMI treatment, a substantial proportion of patients develop LVAR, leading to heart failure and increased MACE risk. Conventional biomarkers (e.g., troponin, NT-proBNP) lack sufficient predictive power for adverse outcomes. Multi-omics approaches - integrating proteomics(e.g., exosome proteomics), metabolomics, transcriptomics and lipidomics - offer a systems-level view that may uncover novel prognostic signatures.

Conditions

Acute Myocardial Infarction (AMI); Left Ventricular Remodeling; Major Adverse Cardiovascular Event; Plasma Multi-Omics

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients with AMI

Patients diagnosed with AMI (ST-segment elevation myocardial infarction \[STEMI\] and non-ST-segment elevation myocardial infarction \[NSTEMI\])

Diagnostic Test: echocardiography and blood collection

Intervention Type: OTHER

Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset.

Interventions

Diagnostic Test: echocardiography and blood collection

Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years.

2. Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).

3. Willingness to provide informed consent.

Exclusion Criteria

1. Prior surgery or trauma.

2. Renal failure with glomerular filtration <30 ml/min.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Anzhen Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xu Wang, Dr.

Role: PRINCIPAL_INVESTIGATOR

Beijing Anzhen hospital, Capital Mediacl University.

Tanxi Cai, Dr.

Role: STUDY_DIRECTOR

Institute of Biophysics, Chinese Academy of Sciences

Locations

Beijing Anzhen Hospital, Capital Medical University.

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

KS2025013

Identifier Type: -

Identifier Source: org_study_id